Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BION-1301 in Japanese Healthy Subjects
NCT05508204Phase 1Completed
- Sponsor
- Chinook Therapeutics
- Start
- Jul 2022
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of zigakibart in IgA nephropathy (IgAN) (3 cohorts), sponsored by Chinook Therapeutics. Primary endpoint: Safety and tolerability of BION-1301 at Day 85. Started Jul 2022; status: completed.
02
Drugs
zigakibart
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT05508204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05508204.